BOARD OF DIRECTORS

Our Board currently consists of eight Directors, comprising three executive Directors, two non-executive Directors and three independent non-executive Directors. The powers and duties of our Board include convening general meetings and reporting our Board's work at our Shareholders' meetings, determining our business and investment plans, preparing our annual financial budgets and final reports, formulating proposals for profit distributions and exercising other powers, functions and duties as conferred by the Articles. We [have entered into] service agreements with each of our executive Directors. We [have also entered] into letters of appointment with each of our non-executive Directors and independent non-executive Directors.

The following table sets forth certain information in respect of members of our Board and senior management of our Group:

Members of our Board

Name	Age	Existing position(s) in our Group	Date of joining our Group	Date of appointment as Director	Roles and responsibilities in our Group
Dr. Du Jinfa (杜錦發)	71	Executive Director, chairman of our Board, chief executive officer and chief scientific officer	January 18, 2019	September 26, 2019	Responsible for the overall management and R&D of our Group
Dr. Dang Qun (黨群)	62	Executive Director, president and chief business officer	March 22, 2021	August 1, 2022	Responsible for business development of our Group and the management of our Shanghai R&D Center
Mr. Wang Lin (王琳)	44	Executive Director and head of our Board office	July 1, 2015	September 26, 2019	Responsible for the administrative management and assisting the chairman in setting strategic goals and planning of our Group
Mr. Zhu Jinqiao (朱晉橋)	59	Non-executive Director	April 12, 2022	April 12, 2022	Responsible for providing guidance and overseeing management and operations of our Group
Dr. Li Juhe (李聚合)	59	Non-executive Director	May 1, 2024	May 1, 2024	Responsible for providing guidance and overseeing management and operations of our Group

Name	Age	Existing position(s) in our Group	Date of joining our Group	Date of appointment as Director	Roles and responsibilities in our Group
Dr. He Ruyi (何如意)	64	Independent non-executive Director	August 1, 2022	August 1, 2022	Responsible for providing independent advice on the management and operations of our Group
Ms. Leung Bik San (梁碧珊)	55	Independent non-executive Director	[●], 2026	[●], 2026	Responsible for providing independent advice on the management and operations of our Group
Mr. Wang Jitao (王繼濤)	53	Independent non-executive Director	[●], 2026	[●], 2026	Responsible for providing independent advice on the management and operations of our Group

Members of our senior management

Name	Age	Existing position(s) in our Group	Date of joining our Group	Date of appointment as senior management	Roles and responsibilities in our Group
Dr. Guo Chang Yue (郭昌月)	63	Senior vice president	May 1, 2019	May 1, 2019	Responsible for the R&D of macromolecular drugs and the management of Shenzhen Genuine
Dr. Li Pan (李磐)	58	Senior vice president	April 12, 2021	April 12, 2021	Responsible for the R&D of small-molecule drugs of our Group

None of the members of Directors and senior management listed above has any relationship with each other.

Executive Directors

Dr. Du Jinfa (杜錦發), aged 71, was appointed as our Director on September 26, 2019 and was re-designated as our executive Director and appointed as chairman of our Board on August 1, 2022. Dr. Du joined our Group in January 2019 and has been serving as our chief executive officer and chief scientific officer since then. He is primarily responsible for the overall management and R&D of our Group and is one of the inventors of azvudine (for the treatment of COVID-19), dosimertinib and CL-197. Dr. Du is also a substantial shareholder of our Company.

Dr. Du has over 31 years of experience in drug discovery in the biotech industry and has been recognized as "State Specially Recruited Experts (國家特聘專家)" by the PRC government. Prior to joining our Group, from 1992 to 1998, Dr. Du was engaged in post-doctorate research of antiviral and anti-tumor drugs at the University of Georgia in the United States. From 2001 to 2011, Dr. Du served at Pharmasset Inc., a clinical-stage pharmaceutical company in the United States principally engaged in discovering, developing and commercializing novel drugs to treat viral infections (previously listed on NASDAQ (previous stock code: VRUS) and subsequently acquired by Gilead Sciences, Inc. (a company principally engaged in research and developing antiviral drugs and listed on NASDAQ (stock code: GILD)) on January 17, 2012), where he served as the associate director of chemical research, and was primarily responsible for leading the R&D project of nucleoside anti-hepatitis C drugs. During such period, Dr. Du, as one of the inventors, participated in the R&D of sofosbuvir (also known as sovaldi), a revolutionary drug for treating hepatitis C which won the Prix Galien Award granted by the Galien Foundation in 2014. The journal *Cell* has commented that sofosbuvir's contribution to the cure of HCV is regarded as one of the most significant public health accomplishments of our generation. From 2012 to 2015, Dr. Du served as the senior research scientist II at Gilead Sciences, Inc., where he was primarily responsible for the research of novel antivirals. From August 2015 to December 2018, Dr. Du served as the chief executive officer and chief scientific officer of Meitaibao, a biotech company founded by Dr. Du himself, where he was primarily responsible for overseeing the R&D of the novel drugs and day-to-day management of the company. During such period, Dr. Du invented two drug candidates, dosimertinib and CL-197. For details of these two drug candidates, please refer to "Business" in this document.

Dr. Du graduated from Changzhou University (常州大學) (formerly known as Jiangsu University of Chemical Technology* (江蘇化工學院)) in the PRC with a bachelor's degree in organic chemical engineering in May 1982. He then graduated from Chinese Academy of Medical Sciences & Peking Union Medical College in the PRC (中國醫學科學院北京協和醫學院) (formerly known as China Union Medical College* (中國協和醫科大學)) ("**Peking Union Medical College**") with a doctor's degree in science in December 1989. As of the Latest Practicable Date, Dr. Du had published 60 academic papers and participated in the invention of more than 300 patents registered worldwide, of which 40 patents had been registered in the United States.

Dr. Dang Qun (黨群), aged 62, was appointed as our executive Director on August 1, 2022. Dr. Dang joined our Group in March 2021 and has been serving as our president and chief business officer since then. He is primarily responsible for business development of our Group and the management of our Shanghai R&D Center.

Dr. Dang has over 31 years of experience in the pharmaceutical and biotech industry. Prior to joining our Group, from October 1992 to 2009, Dr. Dang served as the director of medicinal chemistry of Metabasis Therapeutics, Inc., a biopharmaceutical company principally engaged in discovery, development and commercialization of novel small molecule drugs (previously listed on NASDAQ (previous stock code: MBRX) and subsequently acquired by Ligand Pharmaceuticals Incorporated, a biopharmaceutical company principally engaged in developing technologies to help pharmaceutical companies discover and develop medicines which is listed on NASDAQ (stock code: LGND), on January 28, 2010), where he was primarily responsible for leading the R&D projects of novel drugs. From 2009 to 2016, Dr. Dang served as the director of external collaborative drug discovery projects of Merck Sharp & Dohme Corp., a biopharmaceutical company principally engaged in discovering and developing medicines, vaccines, and other health products, where he was primarily responsible for R&D projects of novel drugs. From February 2016 to March 2018, Dr. Dang served as the Asia head of external innovation for endocrine and cardiovascular system in the Lilly China Research and Development Centre of Eli Lilly and Company, a pharmaceutical company principally engaged in researching and developing innovative drugs and listed on the New York Stock Exchange (stock code: LLY), where he was primarily responsible for the business development in Asia Pacific region. From April 2018 to June 2019, Dr. Dang served as the vice president of Qilu Pharmaceutical Co., Ltd. (齊魯製藥有限公司), a pharmaceutical company principally engaged in the development, manufacturing and marketing of active pharmaceutical ingredients and finished formulations, where he was primarily responsible for business development. From June 2019 to February 2021, Dr. Dang served as the vice president of CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.* (石藥集團中奇製藥技術(石家莊)有限公司), a wholly-owned subsidiary of CSPC Pharmaceutical Group Limited (石藥集團有限公司), a company listed on the Stock Exchange (stock code: 1093) and principally engaged in the development of pharmaceutical products, where he was primarily responsible for R&D of innovative drugs.

Dr. Dang graduated from Jilin University (吉林大學) in the PRC with a bachelor's degree in polymer chemistry in July 1985, and obtained a Ph.D degree from Purdue University in the United States in December 1992. Dr. Dang was awarded with the second prize of Jilin Science and Technology Award (吉林省科學技術獎) by Jilin Science and Technology Award Committee* (吉林省科學技術獎勵委員會) on November 12, 2021 for his contribution to the project of the application of new carbonation chemical synthesis technology in drug R&D.

Mr. Wang Lin (王琳), former name Wang Jialin (王稼霖), aged 44, was appointed as our Director on September 26, 2019 and was re-designated as our executive Director on August 1, 2022. Mr. Wang joined our Group in July 2015 and has been serving as the executive director and legal representative of Henan Genuine since September 2018. He has also been serving as the head of our Board office since June 2023. He is primarily responsible for the administrative management and assisting the chairman in setting strategic goals and planning of our Group.

Mr. Wang has over 15 years of experience in corporate management. Prior to joining our Group, from October 2009 to October 2011, Mr. Wang successively served as a deputy director and director of general office at Henan Fenglin Industrial Group Co., Ltd.* (河南豐麟實業集團有限公司) ("**Henan Fenglin**"), a company principally engaged in investment in metallurgy, energy and technology development projects, where he was primarily responsible for its administrative management and public relations. From February 2011 to October 2012, Mr. Wang was assigned by Henan Fenglin to serve as the general manager of Henan Jiayuan Dairy Co., Ltd.* (河南佳源乳業股份有限公司) ("**Henan Jiayuan**"), a provincial leading agricultural industrialization pilot unit which was controlled by the then shareholders of Henan Fenglin and was principally engaged in the production of dairy and bakery products, where he was primarily responsible for its overall operational management. During his tenure in Henan Jiayuan, Mr. Wang Lin led Henan Jiayuan to achieve a significant increase in sales between 2010 to 2012 by adopting a new "milk + bread" compound retail store model and served as a director, legal representative and/or sole proprietor for nine compound retail stores of Henan Jiayuan during his tenure. From March 2013 to November 2014, Mr. Wang started his own business in real estate marketing and agency industry and invested in Henan Zhuohui Real Estate Sales Co., Ltd. (河南卓輝房地產銷售有限公司), a company principally engaged in the sales of real estate properties. From July 2015 to October 2018, Mr. Wang served as the assistant to the chairman of the board of Xingyu Zhongke, primarily responsible for assisting the chairman of the board in handling company affairs and managing the administrative work of the company. Since November 2018, Mr. Wang has been serving as the deputy general manager of Xingyu Zhongke, primarily responsible for administration and legal affairs, including the preliminary preparation of pharmaceutical investment projects and the production base construction. Since April 2020, Mr. Wang has been primarily responsible for administration and legal affairs, including assisting the chairman of the board in handling the business operation and outreach affairs of Xingyu Zhongke.

Mr. Wang graduated from Zhengzhou University (鄭州大學) in the PRC in accounting through online learning in August 2015.

Mr. Wang was a director or the sole proprietor of the following company and enterprises which were established as self-operated sales channels of Henan Jiayuan during his tenure in Henan Jiayuan for the purpose of its business expansion and were voluntarily dissolved due to the change of business plan of Henan Jiayuan:

Name of company or enterprise	Place of establishment	Nature of business	Details of the proceeding involved
Henan Yishengduo Food Co., Ltd.* (河南益聖多食品有限公司)	PRC	Production and sales of cold and hot beverage	Dissolved on September 13, 2013
Zhengzhou Erqi District Wanglin Bakery* (鄭州市二七區王琳蛋糕店)	PRC	Sales of bread, cake, pastry and moon cake	Dissolved on April 12, 2013

Name of company or enterprise	Place of establishment	Nature of business	Details of the proceeding involved
Weidong District Xintian Jiayuan Food Shop* (衛東區新田佳原食品店)	PRC	Sales of prepackaged food and dairy products (infant formula milk excluded)	Dissolved on July 14, 2012
Zhengzhou Zhongyuan Jiayuan Ranch Bakery* (鄭州市中原區佳源牧場麵包房)	PRC	Sales of bread, cake and prepackaged food	Dissolved on May 12, 2013
Pingdingshan Xinhua District Jingcheng Jiayuan Ranch Bakery* (平頂山市新華區京城佳源牧場蛋糕房)	PRC	Sales of bread, cake, prepackaged food and dairy products (infant formula milk powder excluded)	Dissolved on December 6, 2012
Sole proprietorship No. 411122617328107	PRC	Sales of prepackaged food, bulk food and dairy products (infant formula milk powder excluded)	Dissolved on December 23, 2012
Sole proprietorship No. 411122617323805	PRC	Sales of prepackaged food, bulk food and dairy products (infant formula milk powder excluded)	Dissolved on April 11, 2017
Henan Yishengduo Food Co., Ltd. University Road Branch* (河南益聖多食品有限公司大學路店)	PRC	Production and sales of cold and hot beverage	Dissolved on May 10, 2013
Henan Yishengduo Food Co., Ltd. Jiaotong Road Branch* (河南益聖多食品有限公司交通路店)	PRC	Production and sales of cold and hot beverage	Dissolved on April 15, 2013

Mr. Wang confirmed that each of the above company and enterprises was solvent prior to its dissolution and no claims had been made against him and he was not aware of any threatened or potential claims made against him in connection with the dissolution of the above company and enterprises as of the Latest Practicable Date. He also confirmed that there are no outstanding claims and/or liabilities as a result of the dissolution of the above company and enterprises.

Non-executive Directors

Mr. Zhu Jinqiao (朱晉橋), aged 59, was appointed as our Director on April 12, 2022 and re-designated as our non-executive Director on August 1, 2022. He is mainly responsible for providing guidance and overseeing management and operations of our Group.

Mr. Zhu has over 27 years of experience in investment and entrepreneurship consulting. Prior to joining our Group, from November 1996 to May 2008, Mr. Zhu served as the chairman of the board and general manager of Shenzhen Langfeng Industry Development Co., Ltd.* (深圳市朗峰投資發展有限公司), a company principally engaged in business investment, where he was primarily responsible for making major decisions such as development plan and investment plan. From August 2007 to August 2020, Mr. Zhu served as the chairman of the board and general manager of

Shenzhen Efung Venture Capital Co., Ltd.* (深圳市倚鋒創業投資有限公司), a company principally engaged in venture capital investment and entrepreneurship consulting, where he was primarily responsible for making major decisions such as development plan and investment plan. Since March 2012, Mr. Zhu has been serving as the controller of Efung Capital, one of our [**REDACTED**] Investors, where he is primarily responsible for leading and managing the company team, making decisions on major issues and managing partnership affairs of the funds.

Mr. Zhu graduated from School of Information Communication of Chinese People's Liberation Army National University of Defense Technology* (中國人民解放軍國防科技大學信息通信學院) (formerly known as Chinese People's Liberation Army Communication Command College* (中國人民解放軍通信指揮學院)) in the PRC in June 2010 in communication and information system management. Mr. Zhu also obtained an executive master of business administration degree from Zhongnan University of Economics and Law (中南財經政法大學) in the PRC in June 2011, an executive master of business administration degree from Cheung Kong Graduate School of Business (長江商學院) in the PRC in September 2015 and a doctorate of business administration through distance learning from Paris School of Business in France in December 2025. Mr. Zhu obtained the China Securities Investment Fund Industry Practice Certificate (中國證券投資基金業從業證書) from the Asset Management Association of China (中國證券投資基金業協會) in the PRC in May 2018.

Mr. Zhu has obtained a number of awards, including the "2019-2020 Top 10 Investors in China's Healthcare Industry (2019-2020年度中國醫療健康產業十佳投資人物)" granted by Chinese Venture (融資中國) in August 2020, "2021 Best Investors in Healthcare Industry (2021年度醫療健康行業最佳投資人)"granted by Securities Times (證券時報) in August 2021 and the "2023 Top 30 Most Influential Investors in China" (2023年中國最具影響力的30位投資人) granted by FORTUNE (《財富》) and Zero2IPO Research (清科研究中心) in November 2023.

Mr. Zhu was a director or executive partner of the following companies and partnership which were dissolved during the period when he was one of their directors or executive partner:

Name of company or partnership	Place of establishment	Nature of business	Details of the proceeding involved
Xinyu Yijin Investment Management Center (Limited Partnership) * 新余易金投資管理中心(有限合夥)	PRC	Business investment	Dissolved on January 17, 2018
Shenzhen Tongyong Lianke Investment Co., Ltd.* (深圳市通用聯科投資有限公司)	PRC	Business investment	Dissolved on January 6, 2009
Suzhou Keshan Micro-Electronics Co., Ltd.* (蘇州科山微電子科技有限公司)	PRC	Design, R&D and sales of semiconductor integrated circuit	Dissolved on October 24, 2017
Guangzhou Liansuo Network Technology Co., Ltd.* (廣州市聯索網絡科技有限公司)	PRC	R&D and technical services of computer network technology, wholesale and retail trade and internet information service	Dissolved on June 19, 2014

Name of company or partnership	Place of establishment	Nature of business	Details of the proceeding involved
Shenzhen Langfeng Investment Development Co., Ltd.* (深圳市朗峰投資發展有限公司)	PRC	Business investment and domestic trade	Dissolved on September 14, 2011
Shenzhen Langfeng Property Management Co., Ltd.* (深圳市朗峰物業管理有限公司)	PRC	Property management	Dissolved on March 31, 2011

Mr. Zhu confirmed that each of the above companies and partnership was solvent prior to its dissolution and no claims had been made against him and he was not aware of any threatened or potential claims made against him in connection with the dissolution of the above companies and partnership as of the Latest Practicable Date. He also confirmed that, there are no outstanding claims and/or liabilities as a result of the dissolution of the above companies and partnership.

Dr. Li Juhe (李聚合), aged 59, was appointed as our non-executive Director on May 1, 2024. He is mainly responsible for providing guidance and overseeing management and operations of our Group.

Dr. Li has over 32 years of experience in the financial industry. From July 1991 to September 2008, Dr. Li served as an assistant researcher and researcher at Finance Department of the National Development and Reform Commission* (國家發展和改革委員會財政金融司), a ministerial-level department of the State Council, where he participated in securities policy research and management. From October 2008 to December 2011, Dr. Li served as the deputy mayor of Xianyang Municipal People's Government of Shaanxi Province* (陝西省咸陽市人民政府), where he was primarily responsible for the management of government affairs, including overseeing the municipal price bureau, government affairs information office, financial work office and the financing of government investment projects. From January 2012 to March 2017, Dr. Li successively served as the deputy inspector and deputy director general of the Finance Department of the National Development and Reform Commission, where he was primarily responsible for the management of corporate securities issuance and social credit system construction. From April 2017 to March 2019, Dr. Li served as the vice chairman of the board of directors at China Fund Management Co., Ltd.* (中信建投基金管理有限公司), a company principally engaged in fund raising and asset management, where he was primarily responsible for strategic design and business planning. Since July 2019, Dr. Li has been serving as the managing partner at Beijing Shangrong Capital Management Co., Ltd.* (北京尚融資本管理有限公司), a company principally engaged in investment and asset management, where he was primarily responsible for equity investment, mergers and acquisitions. From October 2019 to October 2023, Dr. Li served as the chairman of the board of directors at Lianrun Credit Services Co., Ltd* (聯潤信用服務有限公司), a company principally engaged in collection and evaluation of enterprise credit, where he was primarily responsible for its enterprise credit management consultation service. Since May 2020, Dr. Li has been serving as an independent director and member of the strategy committee and remuneration committee at China CYTS Tours Holding Co., Ltd.* (中青旅控股股份有限公司), a company principally engaged in tourism services whose shares are listed on the Shanghai Stock Exchange (stock code: 600138), where he is primarily responsible for providing independence advice on its management and operation. Dr. Li became acquainted with our Company through the introduction by Dr. Du and was appointed as our non-executive Director in May 2024.

Dr. Li graduated from Peking University (北京大學) in the PRC with a bachelor's degree in economics in July 1988. He also obtained a master's degree and a doctor's degree in economics from Renmin University of China (中國人民大學) in the PRC in June 1991 and January 2007, respectively.

Dr. Li was a director and manager of Quanlian (Beijing) Capital Management Co., Ltd.* (全聯(北京)資本管理有限公司) ("**Quanlian Capital**") which had not commenced any business since its establishment and was dissolved on February 22, 2023. Dr. Li confirmed that Quanlian Capital was solvent prior to its dissolution and no claims had been made against him and he was not aware of any threatened or potential claims made against him in connection with the dissolution of Quanlian Capital as of the Latest Practicable Date. He also confirmed that there are no outstanding claims and/or liabilities as a result of the dissolution of Quanlian Capital.

Independent non-executive Directors

Dr. He Ruyi (何如意), aged 64, was appointed as our independent non-executive Director on August 1, 2022 and is responsible for providing independent advice on the management and operations of our Group.

Dr. He has over 24 years of experience in medical and pharmaceutical industries. From 1999 to May 2016, Dr. He served at the Center for Drug Evaluation and Research of the Food and Drug Administration in the United States in various capacities, including medical officer, medical team leader and subsequently the acting deputy director of the Division of Gastroenterology and Inborn Error Products. From July 2016 to 2018, Dr. He served as the chief scientist of the Center for Drug Evaluation, NMPA (國家食品藥品監督管理總局藥品審評 中心) in the PRC, where he was primarily responsible for participating in the reform of drug evaluation and approval system in the PRC and supervising assessments related to the safety, effectiveness and quality of innovative drugs. Since 2018, Dr. He has been serving as the chief scientist of life science at SDIC Fund Management Co., Ltd.* (國投創新投資管理有限公司), a company principally engaged in investment management and consulting, where he is primarily responsible for providing advice on investment decisions in the life science fields. Dr. He served as the executive director, chief medical officer and head of clinical research of RemeGen Co., Ltd.* (榮昌生物製藥(煙台)股份有限公司) ("RemeGen"), a biopharmaceutical company principally engaged in producing and developing innovative drugs and listed on the Stock Exchange (stock code: 09995) and the Science and Technology Innovation Board of the Shanghai Stock Exchange (stock code: 688331), from May 2020 to August 2024, where he was primarily responsible for management of clinical medical affairs. From August 2024 to February 2025, Dr. He served as a director and chief strategy officer at RemeGen, where he was primarily responsible for the strategic planning. Dr. He also served as the independent director of BrightGene Bio-Medical Technology Co., Ltd.* (博瑞生物醫藥(蘇州)股份有限公司), an innovative pharmaceutical company listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange (stock code: 688166), from September 2023 to September 2024, and has been serving as the independent director of Suzhou Zelgen Biopharmaceuticals Co., Ltd. (蘇州澤璟生物製藥股份有限公司), a company principally engaged in researching, developing, producing innovative drugs and listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange (stock code: 688266), since February 2019.

Dr. He graduated from China Medical University (中國醫科大學) in the PRC with bachelor's and master's degrees in medicine in August 1983 and July 1986, respectively. Dr. He graduated from Howard University in the United States with a certification of postgraduate medical education in internal medicine in June 1999. Dr. He was once certified as a diplomate in internal medicine in the United States in 1999, and was licensed as a medical doctor in the State of Virginia from October 1998 to March 2006, and in the State of West Virginia from March 2015 to September 2020 in the United States.

Ms. Leung Bik San (梁碧珊), aged 55, was appointed as our independent non-executive Director on [●], 2026 and is responsible for providing independent advice on the management and operations of our Group.

Ms. Leung has over 30 years of experience in audit, capital market, regulatory and compliance and corporate finance. From February 1993 to January 1997, Ms. Leung served as an audit assistant, audit senior and subsequently the audit supervisor of Grant Thornton Byrne, an accounting firm, where she was primarily responsible for providing audit services. From January 1997 to April 2001, Ms. Leung served at KPMG, an international accounting firm, with her last position as the manager, where she was primarily responsible for audit management and financial reports. From April 2001 to October 2009, Ms. Leung served at Fox-Pitt, Kelton (Asia) Limited, an investment bank, where she was primarily responsible for overseeing the business operation and financial management. From November 2009 to October 2012, Ms. Leung served at Keefe, Bruyette & Woods Asia Limited, an investment bank, with her last position as the chief operating officer, where she was primarily responsible for overseeing the overall operations and formulating business strategies.

Since January 2013, Ms. Leung has been serving as the chief financial officer at Canaccord Genuity (Hong Kong) Limited, a financial service provider, where she is primarily responsible for the overall financial management and operational management of the Hong Kong office. Ms. Leung has also been serving as the independent non-executive director of Lushang Life Services Co., Ltd.* (魯商生活服務股份有限公司, a property management service provider listed on the Stock Exchange (stock code: 02376), since June 2022.

Ms. Leung graduated from University of New South Wales in Australia with a bachelor's degree in commerce in April 1993. Ms. Leung received her master's degree in business administration from University of Warwick in the United Kingdom in June 2009. Ms. Leung was certified as a certified practising accountant of the CPA Australia in May 1996 and a member of the Hong Kong Institute of Certified Public Accountants (formerly known as the Hong Kong Society of Accountants) in September 1996.

Mr. Wang Jitao (王繼濤), aged 53, was appointed as our independent non-executive Director on [●], 2026 and is responsible for providing independent advice on the management and operations of our Group.

Mr. Wang has over 22 years of experience in the legal profession. Mr. Wang has been serving in Henan Yitianjian Law Firm* (河南倚天劍律師事務所) as a lawyer since December 1999 and as a partner since September 2005, where he is primarily responsible for providing legal advice.

Mr. Wang held or holds various positions in public organizations, including an honorary professor of School of Law of Henan University of Urban Construction (河南城建學院) since May 2011, an expert member of Pingdingshan Social Organization Standardization Construction Evaluation Committee* (平頂山市社會組織規範化建設評估委員會) since December 2012, a legal consultant of Political and Legal Committee of Pingdingshan Municipal Committee of the Chinese Communist Party* (中共平頂山市委政法委員會) since March 2017, a member of the Eleventh Standing Committee of Pingdingshan Municipal People's Congress (平頂山市第十一屆人民代表大會常務委員會) from September 2018 to January 2023, a member of the Expert Advisory Committee of Pingdingshan People's Procuratorate* (平頂山市人民檢察院專家諮詢委員會) since December 2018, a member of the Legal Advisory Committee of the Internal and Judicial Affairs Committee of the Eleventh and Twelfth Standing Committee of Pingdingshan Municipal People's Congress* (平頂山市第十一屆、十二屆人大常委會內務司法工作委員會法律諮詢委員會) since August 2019, a member of the Working Committee of Henan Lawyers Association* (河南省律師協會工作委員會) since May 2020, a law enforcement supervisor of the Public Security Bureau of Pingdingshan (平頂山市公安局) since September 2020, a business environment supervisor appointed by Pingdingshan Leading Group Office for Optimizing Business Environment* (平頂山市優化營商環境工作領導小組辦公室) since July 2021, a member of the Twelfth Standing Committee of Pingdingshan Municipal People's Congress* (平頂山市第十二屆人民代表大會常務委員會) since January 2023, a member of the Legislative Affairs Commission of the Twelfth Standing Committee of Pingdingshan Municipal People's Congress* (平頂山市第十二屆人民代表大會法制委員會) since January 2023 and a supervisor of Henan Lawyers Association* (河南省律師協會) since December 2025.

Mr. Wang graduated from The Open University of China (國家開放大學) (formerly known as Central Radio and Television University (中央廣播電視大學)) in the PRC in July 2003 in law. Mr. Wang was certified as a lawyer by Ministry of Justice of the PRC since 1999.

Each of our Directors has confirmed that he/she obtained the legal advice on February 14, 2025 with regards to the requirements under the Listing Rules that are applicable to him/her as a director of a listed issuer and the possible consequences of making a false declaration or giving false information to the Stock Exchange as set out in Rule 3.09D of the Listing Rules and he/she understood his/her obligations as a director of a listed issuer.

Each of our independent non-executive Directors has confirmed his/her independence with regards to each of the factors as set out in Rule 3.13(1) to (8) of the Listing Rules and that there are no other factors that may affect his/her independence at the time of his/her appointment.

SENIOR MANAGEMENT

Dr. Guo Chang Yue (郭昌月), aged 63, joined our Group on May 1, 2019. Dr. Guo served as our vice president from May 2019 to January 2026 and has been serving as our senior vice president and the general manager of Shenzhen Genuine since February 2026. He is mainly responsible for the R&D of macromolecular drugs and the administrative management of Shenzhen Genuine.

Dr. Guo has over 30 years of experience in the clinical and medicine field. Prior to joining our Group, from September 1992 to 1994, Dr. Guo served as an assistant professor (助理研究員) of Peking Union Medical College (北京協和醫學院), where he was primarily responsible for medical research. From 1994 to 2009, Dr. Guo served at University of Virginia Health System in the United States, where he was primarily responsible for medical research and clinical practice. From March 2016 to July 2019, Dr. Guo served as a physician and the international medical center director of Shenzhen Vista-SK International Medical Co., Ltd.* (深圳維世達勝凱國際有限公司), where he was primarily responsible for providing clinical treatment.

Dr. Guo graduated from School of Medicine, Wuhan University* (武漢大學醫學部) (formerly known as Hubei Medical College* (湖北醫學院)) in the PRC with a bachelor's degree in medicine in August 1983. Dr. Guo received his master's degree in medicine from China Medical University (中國醫科大學) in the PRC in July 1988. Dr. Guo graduated from Peking Union Medical College in the PRC in August 1992, where he majored in pharmacology as a Ph.D student. Dr. Guo obtained a doctor's degree of medicine from Ross University School of Medicine in the United States in March 2014. As of the Latest Practicable Date, Dr. Guo had published 15 high-quality academic papers in international authoritative academic journals and held multiple invention patents.

Dr. Li Pan (李磐), aged 58, joined our Group on April 12, 2021. Dr. Li served as our vice president from April 2021 to January 2026 and has been serving as our senior vice president since February 2026. He is mainly responsible for the R&D of small-molecule drugs of our Group.

Dr. Li has over 23 years of experience in R&D of novel drugs. Prior to joining our Group, from August 2000 to February 2017, Dr. Li served as a research fellow at Vertex Pharmaceuticals, Inc., a company principally engaged in developing and commercializing therapies for the treatment of cystic fibrosis and listed on NASDAQ (stock code: VRTX), where he was primarily responsible for design and synthesis of novel drugs. From July 2017 to August 2019, Dr. Li served as the executive director of the medicinal chemistry department of Adlai Nortye Biopharma Co., Ltd. (杭州阿諾生物醫藥科技有限公司), a company principally engaged in R&D of pharmaceuticals and listed on NASDAQ (stock code: ANL), where he was primarily responsible for research. From September 2019 to April 2021, Dr. Li served as the vice general manager of Shanghai Yishi Medical Technology Co., Ltd.* (上海翊石醫藥科技有限公司), a subsidiary of CSPC Pharmaceutical Group Limited, a pharmaceutical company listed on the Stock Exchange (stock code: 1093), where he was primarily responsible for R&D of small-molecule novel drugs.

Dr. Li graduated from University of Science and Technology of China (中國科學技術大學) in the PRC with a bachelor's degree in polymer chemistry in July 1988, and obtained a Ph.D degree from New York University in the United States in September 1998.

COMPANY SECRETARY

Ms. Leung Wai Yan (梁慧欣), was appointed as the company secretary of our Company on August 1, 2022 and is responsible for company secretarial matters of our Company.

Ms. Leung has over 18 years of experience in providing company secretarial services and compliance services to listed companies and private companies. Since November 2020, she has been serving at Vistra Corporate Services (HK) Limited, a company principally engaged in providing corporate business services, with her current position as the manager, where she is primarily responsible for providing full range of company secretarial services. Ms. Leung is currently serving as the company secretary at Akeso, Inc. (康方生物科技(開曼)有限公司), a company listed on the Main Board of the Stock Exchange (stock code: 9926), and a joint company secretary at Cryofocus Medtech (Shanghai) Co., Ltd. (康灃生物科技(上海)股份有限公司), a company listed on the Main Board of the Stock Exchange (stock code: 6922), Powerlong Real Estate Holdings Limited (寶龍地產控股有限公司), a company listed on the Main Board of the Stock Exchange (stock code: 1238) and Powerlong Commercial Management Holdings Limited (寶龍商業管理控股有限公司), a company listed on the Main Board of the Stock Exchange (stock code: 9909).

Ms. Leung obtained a master of laws majoring in corporate and financial law from The University of Hong Kong in July 2024 and graduated from University of South Australia in Australia with a bachelor's degree in business (administrative management) in April 2004. Ms. Leung has been an associate member of The Hong Kong Chartered Governance Institute and an associate member of The Chartered Governance Institute in the United Kingdom since October 2009.

BOARD COMMITTEES

Our Board [has established] the Audit Committee, the Remuneration Committee and the Nomination Committee and delegated various responsibilities to these three committees, which assist our Board in discharging its duties and overseeing particular aspects of our activities.

Audit Committee

We established the Audit Committee on [●], 2026 pursuant to Rule 3.21 of the Listing Rules with written terms of reference in compliance with paragraph D.3 of Part 2 of the Corporate Governance Code ("**CG Code**") as set forth in Appendix C1 to the Listing Rules. The Audit Committee consists of three members, namely Mr. Wang Jitao, Ms. Leung Bik San and Dr. Li Juhe. Mr. Wang Jitao is the chairman of the Audit Committee. Ms. Leung Bik San has the appropriate professional qualifications or accounting or related financial management expertise as required under Rule 3.10(2) of the Listing Rules.

The primary duties of the Audit Committee are to provide an independent view of the effectiveness of our financial reporting, risk management and internal control systems, oversee our audit process, develop and review policies and perform other duties and responsibilities as assigned by our Board.

Remuneration Committee

We established the Remuneration Committee on [●], 2026 pursuant to Rule 3.25 of the Listing Rules with written terms of reference in compliance with paragraph E.1 of Part 2 of the CG Code as set forth in Appendix C1 to the Listing Rules. The Remuneration Committee consists of three members, namely Dr. He Ruyi, Mr. Wang Jitao and Dr. Li Juhe. Dr. He Ruyi is the chairman of the Remuneration Committee.

The primary duties of the Remuneration Committee are to (i) establish, review and advise our Board on our policy and structure of remuneration of our Directors and senior management; (ii) establish a formal and transparent procedure for developing policies concerning such remuneration; (iii) determine the terms of remuneration packages for each Director and senior management officer; and (iv) review and approve performance-based remuneration by reference to corporate goals and objectives as resolved by our Directors from time to time.

Nomination Committee

We have established the Nomination Committee on [●], 2026 pursuant to Rule 3.27A of the Listing Rules with written terms of reference in compliance with paragraph B.3 of Part 2 of the CG Code as set forth in Appendix C1 to the Listing Rules. The Nomination Committee consists of three members, namely Dr. Du Jinfa, Ms. Leung Bik San and Dr. He Ruyi. Dr. Du Jinfa is the chairman of the Nomination Committee.

The primary duties of the Nomination Committee are to (i) review the structure, size and composition of our Board on a regular basis and make recommendations regarding any proposed changes to its composition; (ii) identify, select or make recommendations to our Board on the selection of nominees for directorship; (iii) ensure the diversity of our Board; (iv) assess the independence of our independent non-executive Directors; and (v) make recommendations to our Board on relevant matters relating to the appointment, re-appointment, removal and succession of our Directors.

BOARD DIVERSITY POLICY

Our Board has adopted a board diversity policy which sets out the approach to achieve diversity on our Board. Our Company recognizes and embraces the benefits of having a diverse Board and sees increasing diversity at the Board level as an essential element in supporting the attainment of our Company's strategic objectives and sustainable development. Our Company seeks to achieve Board diversity through the consideration of a number of factors, including but not limited to gender, age, cultural and educational background, ethnicity, professional experience, skills, knowledge and length of service. All Board appointments will be based on meritocracy and candidates will be considered against objective criteria, having due regard to the benefits of diversity on our Board.

Our Directors have a balanced mix of knowledge, skills and experiences, including R&D and production of pharmaceuticals, corporate management, investment and entrepreneurship consulting, audit, regulatory and compliance, corporate finance and legal professional skills. Members of our board have obtained degrees in various majors including organic chemical engineering, science, polymer chemistry, medicine, commerce, economics, business administration, law, accounting, communication and information system management. Furthermore, the ages of our Directors range from 43 years old to 70 years old.

Regarding the gender diversity on our Board, we recognize the particular importance of gender diversity. Our Board currently comprises one female Director and seven male Directors. We have taken and will continue to take steps to promote and enhance gender diversity at all levels of our Company, including but without limitation at our Board and senior management levels. Our board diversity policy provides that our Board should aim to increase the proportion of female members over time after [**REDACTED**] where possible when selecting and making recommendations on suitable candidates for Board appointments. We will also ensure that there is gender diversity when recruiting staff at mid to senior level so that we will have a pipeline of female senior management and potential successors to our Board going forward. It is our objective to maintain an appropriate balance of gender diversity with reference to the expectations of stakeholders and international and local recommended best practices.

Our Nomination Committee is responsible for ensuring the diversity of our Board members. After [**REDACTED**], our Nomination Committee will review our board diversity policy and its implementation from time to time to monitor its continued effectiveness and we will disclose the implementation of our board diversity policy, including any measurable objectives set for implementing the board diversity policy and the progress on achieving these objectives, in our corporate governance report on an annual basis.

KEY TERMS OF EMPLOYMENT CONTRACTS

We normally enter into employment contracts, confidentiality and non-competition agreements with our senior management members and other key personnel. Below sets forth the key terms of these contracts we enter into with our senior management and other key personnel.

Term

- We usually enter into a three-year employment contract with our senior management members and other key personnel. Either party may terminate the employment contract by giving not less than one month's written notice to the other party.

Confidentiality

- The employee shall not copy, take away or disseminate outside our Group any documents, records, memos, plans, drawings, customer lists, financial information, supplier information or marketing materials and shall return the same together with any information related to the work results during the employment period to our Group upon termination of the employment contract.

- During the term of the employment contract and within two years upon termination of the employment contract, the employee shall keep in confidence and shall not disclose to any person without the written consent of our Group, among other things, any information related to planning and design, product R&D, work results, company management systems, work processes, marketing plans, real estate or assets information and any other confidential information related to our Group.

Non-competition

- We have entered into non-competition agreements with our key employees, according to which our key employees may not conduct business in direct or indirect competition with us during the term of their employment and may not compete with us (in the ways stipulated in the agreements) in China for two years after the termination of such employment.

CORPORATE GOVERNANCE

Our Company aims to achieve high standards of corporate governance which are crucial to the development and safeguard the interests of our Shareholders. To accomplish this, our Company expects to comply with the Corporate Governance Code as set out in Appendix C1 to the Listing Rules and the relevant Listing Rules after [**REDACTED**], save for the deviation as mentioned below. Any deviation from the code provisions shall be carefully considered, and the reasons for any deviation and explanation of how good corporate governance was achieved by means other than strict compliance with the code provisions shall be given in the interim report and the annual report in respect of relevant period.

According to code provision C.2.1 of Part 2 of the CG Code in Appendix C1 to the Listing Rules, the roles of chairman and chief executive should be separate and should not be performed by the same individual. Dr. Du is currently the chairman and chief executive officer of our Company. In view of the fact that Dr. Du has been assuming the responsibilities in the overall management and R&D of our Group since January 2019, our Board believes that it is in the best interest of our Group to have Dr. Du taking up both roles for effective management and operations. Therefore, our Directors consider that the deviation from such code provision is appropriate. Notwithstanding such deviation, our Directors are of the view that our Board is able to work efficiently and perform its responsibilities with all key and appropriate issues discussed in a timely manner. In addition, as all major decisions will be made in consultation with members of our Board and the relevant Board committees, and there are three independent non-executive Directors on our Board offering independent perspective, our Board is therefore of the view that there are adequate safeguards in place to ensure sufficient balance of powers within our Board. Our Board shall nevertheless review the structure and composition of our Board and senior management from time to time in light of prevailing circumstances to maintain a high standard of corporate governance practices of our Company.

COMPENSATION OF DIRECTORS AND SENIOR MANAGEMENT

Our Directors and members of our senior management receive compensation in the form of salaries, bonuses and other benefits in kind such as contributions to pension plans.

The aggregate remuneration (including fees, salaries, bonuses, allowances and benefits in kind and pension scheme contributions) paid to our Directors for each of the two years ended December 31, 2025 was RMB10.4 million and RMB10.3 million, respectively. Save as disclosed above, no other amounts have been paid or are payable by any member of our Group to our Directors for such periods.

The aggregate remuneration (including salaries, bonuses, allowances and benefits in kind, equity-settled share-based payment expenses and pension scheme contributions) paid to our five highest paid individuals for each of the two years ended December 31, 2025 was RMB15.4 million and RMB19.9 million, respectively.

Mr. Liu Yong, our former executive Director and vice president, and Ms. He Binyuan, our former vice president, tendered his and her resignation in September 2023 and January 2024, respectively, due to their personal reasons. Save for the compensation of RMB1,000,000 for loss of office paid to each of Mr. Liu Yong and Ms. He Binyuan for the purpose of rewarding their contribution in the management of our Group, no remuneration was paid by us to our Directors or the five highest paid individuals as an inducement to join or upon joining us or as a compensation for loss of office for the two years ended December 31, 2025. Further, none of our Directors had waived or agreed to waive any remuneration during the same periods.

Under the arrangement currently in force, the aggregate remuneration (including fees, salaries, bonus, allowances and benefits in kind, equity-settled share-based payment expenses and pension scheme contributions) to our Directors for the year ending December 31, 2026 is estimated to be no more than approximately RMB10.7 million.

Our Board will review and determine the remuneration and compensation packages of our Directors and senior management officers with, following the [**REDACTED**], the benefit of recommendations from the Remuneration Committee. Our Remuneration Committee will take into account salaries paid by comparable companies, time commitment and responsibilities of our Directors and performance of our Group.

COMPLIANCE ADVISOR

In compliance with Rule 3A.19 of the Listing Rules, we have appointed Guotai Junan Capital Limited as our compliance advisor. We expect that our compliance advisor will, amongst other things, advise our Company with due care and skill in the following circumstances:

- before the publication of any regulatory announcement, circular or financial report;
- where a transaction, which might be a notifiable or connected transaction, is contemplated, including shares issues, sales or transfers of treasury shares and share buybacks;
- where we propose to use the [**REDACTED**] from the [**REDACTED**] in a manner different from that detailed in this document or where our business activities, developments or results deviate from any forecast, estimate, or other information in this document; and
- where the Stock Exchange makes an inquiry of us under Rule 13.10 of the Listing Rules.

The term of appointment of our compliance advisor shall commence on the [**REDACTED**] and end on the date on which we distribute our annual report in respect of our financial results for the first full financial year commencing after the [**REDACTED**].